Cell Therapeutics and Sunesis Eager to Earn Blockbuster Status
April 12 2011 - 7:16AM
Marketwired
There is plenty of optimism surrounding the biotech sector as
firmer pricing and new products have improved sales and earnings
trends. Meanwhile, younger, more speculative firms continue to
garner significant attention with potential blockbuster products
working their way through the regulatory process. The Bedford
Report examines the outlook for companies in the Biotechnology
Industry and provides research reports on Cell Therapeutics, Inc.
(NASDAQ: CTIC) and Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS).
Access to the full company reports can be found at:
www.bedfordreport.com/2011-04-CTIC
www.bedfordreport.com/2011-04-SNSS
IMS Health, a leading research and analytical firm serving the
pharmaceutical and medical industries, projects an increase in
worldwide biotech growth in 2011 of between 5 and 7 percent, with a
similar outlook stretching out to 2015. Emerging markets such as
China, India, and Brazil are expected to contribute significantly
to this growth. Sales growth of 15 percent is forecast in emerging
markets, many of which are benefitting from increased government
spending on healthcare and broader private health coverage for
workers.
The Bedford Report releases regular market updates on the
Healthcare Sector so investors can stay ahead of the crowd and make
the best investment decisions to maximize their returns. Take a few
minutes to register with us free at www.bedfordreport.com and get
exclusive access to our numerous analyst reports and industry
newsletters.
Cell Therapeutics recently said that it will spend $10 million
to buy rights to an anti-cancer drug owned by Chroma Therapeutics.
Cell Therapeutics said that in trials, Chroma's drug had
"demonstrated significant anti-tumor responses in blood related
cancers and solid tumors."
Cell Therapeutics has its own potential blockbuster drug working
its way through the regulatory process. Although the company's
"pixantrone" drug for non-Hodgkin's lymphoma failed to gain FDA
approval last year, CTIC is preparing to start a new clinical trial
of the drug.
The Bedford Report provides Analyst Research focused on equities
that offer growth opportunities, value, and strong potential
return. We strive to provide the most up-to-date market activities.
We constantly create research reports and newsletters for our
members. The Bedford Report has not been compensated by any of the
above-mentioned publicly traded companies. The Bedford Report is
compensated by other third party organizations for advertising
services. We act as an independent research portal and are aware
that all investment entails inherent risks. Please view the full
disclaimer at http://www.bedfordreport.com/disclaimer
Add to Digg Bookmark with del.icio.us Add to Newsvine
Contact: The Bedford Report Email Contact
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Sep 2023 to Sep 2024
Real-Time news about Sunesis Pharmaceuticals Inc (NASDAQ): 0 recent articles
More The Bedford Report News Articles